Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag

Egis Gyogyszergyar Rt.

Richter Gedeon Vegyeszeti Gyar Rt

Egis Gyogyszergyar

Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag

Egis Gyogyszergyar Nyilvanosan Muekoedoe

Byogal Gyogyszergyar

Ferenc Lorant Bartha

Gyula Simig

Jozsef Barkoczy

Kalman Nagy

Balazs Volk

Adrienn Keszthelyi

Tibor Mezei

Jozsef Fetter

Kálmán Nagy

Karoly Lempert

Gyula Hornyak

Gabor Doleschall

Karoly Zauer

Péter Trinka

Gyula Lukacs

Jozsef Nyitrai

Gyorgy Krasznai

Janos Imre

Gyorgy Ruzsics

Eva Sipos

Gyoergy Ruzsics

Lujza E Petocz

Tibor Szabo

Katalin Grasser

Jozsef Reiter

Márta Porcs-Makkay

Laszlo Pongo

Pal Vago

Gyula Lukács

Györgyi Vereczkeyné Donáth

Maria Tothne Lauritz

Zsuzsanna Szent-Királlyi

Zoltán Katona

Gyoergyi Kovanyine Lax

Gyorgyi Kovanyine Lax

Antal Feller

Edit Nee Berenyi

Norbert Nemeth

Zsuzsanna Orr

Zsuzsa Szent Kirallyi

József Reiter

Peter Kotay Nagy

László Pongó

Imre Kiraly

Gyoergy Clementis

Peter Slegel

Jozsef Debreczeni

Györgyi Vereczekeyné Donath

Etelka Pjeczka

Eniko Szirt

Peter Huszthy

Gyula Siming

György Ruzsics

Enikö Molnár

Gyorgy Morovjan

Gabor Bagyinszki

Gyoergy Morovjan

Gyoergy Krasznai

Peter Tömpe

Gyōrgy Clementis

Valeria Hoffmanne Fekete

Gyōrgyi Vereczkeyne Donath

Adrienn Karasz

Györgyi Vereczkeyne Donath

Zsuzsanna Évinger

Lászlö Pongo

Enikö Molnar

Jozsef BARKÓCZY

Judit Cselenyak

Péter Kótay Nagy

Gyorgyi Vereczkeyn Donáth

Donáth Györgyi Vereczkeyné

The present invention is related to intermediates useful in the preparation of pharmaceutically acceptable salts of (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-(3R,5S)-dihydroxy-hept-6-enoic acid and polymorphs of said intermediates, methods for preparation thereof and use thereof.

Method for the preparation of high-purity pharmaceutical intermediates

The present invention is related to methods for the preparation of pharmaceutically acceptable salts of (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-(3R,5S,6E)-dihydroxy-hept-6-enoic acid, intermediates thereof and methods for producing said intermediates.

Method for preparing rosuvastatin salts

The present invention relates to crystalline Form I rosuvastatin zinc (2:1) salt, method of preparation thereof and use thereof as pharmaceutically active ingredient for the treatment of diseases related to lipid metabolism including hyperlipoproteinemia, hypercholesteremia, dyslipidemia and atherosclerosis.

Crystalline form I rosuvastatin zinc salt

The present invention relates to a new process for the preparation of rosuvastatin [7-[4-(4-Fluorophenyl)-6-isopropyl-2-(methanesulphonyl-methyl-amino)-pyrimidin-5-yl]-(3R,51S)-dihydroxy-hept-6-enoic acid] of the formula (I) salts formed with bivalent cations, preferably with calcium or zinc ions, characterized in that rosuvastatin tert.-butylammonium salt is reacted with the appropriate bivalent cation, preferably with calcium or zinc ions in a mixture of a water immiscible or slightly miscible organic solvent and water and the formed salt is isolated. 

Process for the preparation of rosuvastatin salts

According to the present invention, 2-chloroethoxy-acetic acid-N,N-dimethylamide of the Formula (I) is prepared by reacting 2-hydroxyethoxy-acetic acid-N,N-dimethylamide of the Formula (II) in a solvent optionally in the presence of a catalyst with thionyl chloride and removing the solvent by distillation. 

[object Object]

The present invention is related to 1-[(4-chlorophenyl)-phenylmethyl]-4-(2,2,2-trichloroethoxycarbonyl)-piperazine of the Formula (IV) and optically isomers thereof, process for preparation thereof and the use of the compound of the Formula (IV) in the preparation of 1-(4-chlorophenyl)-phenylmethyl-piperazine and optical isomers and salts thereof. 1-(4-chlorophenyl)-phenylmethyl-piperazine and optical isomers thereof are important intermediates in the preparation of non-sedating antihistamine-type active pharmaceutical ingredients. 

Optically active carbamates, process for preparation thereof and use thereof as pharmaceutical intermediates

The invention relates to new crystalline forms I and II of (4R-cis)-6-[2-[3-phenyl-4-(phenyl-carbamoyl)-2-(4-fluoro-phenyl)-5-(1- methyl-ethyl)-pyrrol-1-yl]-ethyl]-2,2-dimethyl-[1,3]dioxane-4-yl-acetic acid-tertiary butyl ester of the Formula (I) and a process for the preparation thereof. The new polymorphs of the present invention are useful pharmaceutical intermediates which can be used in the preparation of the hydroxymethyl-glutaryl coenzyme (HMG-COA) reducing enzyme inhibitor having the INN (International Non-proprietory Name) atorvastatin 

Polymorphs of a 1-pyrrole derivative, intermediate for the preparation of atorvastatin

The invention refers to a novel process for the preparation of {2-[-(&#x3b1;-phenyl-p-chlorobenzyl)piperazin-1-yl]ethoxy}acetic acid, which comprises hydrolyzing an N,N-disubstituted {2-[-(&#x3b1;-phenyl-p-chlorobenzyl)piperazin-1-yl]ethoxy}acetamide, wherein said substituents are selected from alkyl groups having 1 to 4 carbon atoms optionally substituted by a phenyl group, alkenyl groups having 2 to 4 carbon atoms or cyclohexyl groups, or the substituents together with the adjacent nitrogen atom of the acetoamido group, form a morpholino group.

Process for the preparation of {2-[4-&#x3b1;-phenyl-p-chlorobenzyl)piperazin-1-yl]ethoxy} acetic acid and novel intermediates therefor

The invention relates to novel iminothiazolidine derivatives of the formula (I), ##STR1## wherein R.sup.1 and R.sup.3 represent, independently from each other, hydrogen or lower alkyl group,

Iminothiazolidine derivatives

The invention relates to compounds of the general formula (X) ##STR1## wherein R is as a removable protecting substituent of the amido group a phenyl group or a benzyl group substituted by one or more alkoxy group(s) having 1-4 carbon atoms and

Azetidinone acetic acid derivatives and process for the preparation

Growing community of inventors

Tiszavasvari, Hungary

Ferenc Lorant Bartha